Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720382 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 703
- Enrollment target
NCT00720382 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 703 participants.
The verdict
NCT00720382, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 703 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.
Interventions
- DRUG Mometasone furoate
- DRUG 0.15% azelastine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 703 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720382
The ClinicalTrials.gov registry entry for NCT00720382 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 703 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mometasone furoate is the first listed.
NCT00720382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720382 about?
NCT00720382 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis". The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.
What is the current status of trial NCT00720382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 703 participants. The study started on 2007-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00720382?
The interventions under investigation include: Mometasone furoate (DRUG), 0.15% azelastine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00720382?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.